

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	04.12.2023	766827-00018	Date of first issue: 16.06.2016

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier					
Trade name	:	Cephapirin / Prednisolone Formulation			
Other means of identification	:	Mastiplan (A011329)			
1.2 Relevant identified uses of th	ne s	substance or mixture and uses advised against			
Use of the Sub- stance/Mixture	:	Veterinary product			
Recommended restrictions on use	:	Not applicable			
1.3 Details of the supplier of the	sat	iety data sheet			
Company	:	MSD Kilsheelan Clonmel Tipperary, IE			
Telephone	:	353-51-601000			
E-mail address of person responsible for the SDS	:	EHSDATASTEWARD@msd.com			
1.4 Emergency telephone number 1-908-423-6000					
SECTION 2: Hazards identific	SECTION 2: Hazards identification				
2.1 Classification of the substance or mixture					

Classification (REGULATION (EC) No 1272/2008)

Respiratory sensitisation, Category 1

H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled.

2.2 Label elements

 Labelling (REGULATION (EC) No 1272/2008)

 Hazard pictograms

Signal word

Hazard statements

H334 May cause allergy or asthma symptoms or breathing

Danger

1

÷



Version 5.2	Revision Date: 04.12.2023	SDS Number: 766827-00018	Date of last issue: 30.09.2023 Date of first issue: 16.06.2016
		difficulties if inha	led.
Preca	utionary statements	keep comfortable	f experiencing respiratory symptoms: Call a

Hazardous components which must be listed on the label: Cefapirin

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

oomponenta			
Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Cefapirin	21593-23-7 244-466-5	Resp. Sens. 1A; H334	>= 1 - < 10
prednisolone	50-24-8 200-021-7	Acute Tox. 4; H302 Repr. 2; H361d STOT RE 1; H372 (Bone marrow, Ad- renal gland, Liver) Aquatic Chronic 2; H411	>= 0.25 - < 1

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

Version 5.2	Revision Date: 04.12.2023	SDS Number: 766827-00018	Date of last issue: 30.09.2023 Date of first issue: 16.06.2016		
		vice immediat When sympto advice.	ely. ms persist or in all cases of doubt seek medical		
Protection of first-aiders		and use the re	First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).		
If inhaled		If not breathin If breathing is	If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical attention.		
In cas	e of skin contact	of water. Remove conta Get medical a Wash clothing	tact, immediately flush skin with soap and plenty aminated clothing and shoes. ttention. before reuse. ean shoes before reuse.		
In cas	se of eye contact		th water as a precaution. ttention if irritation develops and persists.		
lf swa	llowed	Get medical a	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.		
4.2 Most i	mportant symptoms	s and effects, both a	cute and delayed		
Risks		: May cause all ties if inhaled.	ergy or asthma symptoms or breathing difficul-		
		other respirate	posure may aggravate preexisting asthma and bry disorders (e.g. emphysema, bronchitis, reac- ysfunction syndrome).		
4.3 Indica	tion of any immedia	te medical attention	and special treatment needed		
Treat	ment	: Treat symptor	natically and supportively.		

SECTION 5: Firefighting measures

5.1 Extinguishing media		
Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
Unsuitable extinguishing media	:	None known.



Vers 5.2	sion	Revision Date: 04.12.2023		DS Number: 6827-00018	Date of last issue: 30.09.2023 Date of first issue: 16.06.2016
5.2 Special hazards arising from the substance or mixture					xture
	Specific hazards during fire- fighting		:	Exposure to com	pustion products may be a hazard to health.
	Hazardous combustion prod- ucts		:	Carbon oxides Metal oxides Silicon oxides	
5.3	Advice	for firefighters			
	Special protective equipment for firefighters		:		e, wear self-contained breathing apparatus. tective equipment.
	Specifi ods	c extinguishing meth-	:	Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to o so. Evacuate area.	

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

barriers).

Personal precautions	Use personal protective equipment. Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).
6.2 Environmental precautions	
Environmental precautions	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil

cannot be contained.

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

6.3 Methods and material for containment and cleaning up

Methods for cleaning up	 Soak up with inert absorbent material. For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
-------------------------	--

SAFETY DATA SHEET according to Regulation (EC) No. 1907/2006, as amended by



Commission Regulation (EU) 2020/878

Cephapirin / Prednisolone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	04.12.2023	766827-00018	Date of first issue: 16.06.2016

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling **Technical measures** See Engineering measures under EXPOSURE : CONTROLS/PERSONAL PROTECTION section. Local/Total ventilation Use only with adequate ventilation. Avoid breathing mist or vapours. Advice on safe handling : Do not swallow. Avoid contact with eyes. Avoid prolonged or repeated contact with skin. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Keep container tightly closed. Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitisers. Take care to prevent spills, waste and minimize release to the environment. If exposure to chemical is likely during typical use, provide eye Hygiene measures flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. 7.2 Conditions for safe storage, including any incompatibilities Requirements for storage Keep in properly labelled containers. Keep tightly closed. : areas and containers Store in accordance with the particular national regulations. Advice on common storage Do not store with the following product types:

7.3 Specific end use(s)

Specific use(s)

: No data available

Gases

Strong oxidizing agents

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form	Control parameters	Basis	
------------	---------	------------------	--------------------	-------	--

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

Version	Revision Date: 04.12.2023	SDS Number:	Date of last issue: 30.09.2023
5.2		766827-00018	Date of first issue: 16.06.2016

		of exposure)		
Glyceryl monos-	123-94-4	OELV - 8 hrs	10 mg/m3	IE OEL
tearate		(TWA)		
Cefapirin	21593-23-7	TWA	0.4 mg/m3 (OEB 2)	Internal
	Further inform	nation: RSEN		
prednisolone	50-24-8	TWA	10 µg/m3 (OEB 3)	Internal
		Wipe limit	100 µg/100 cm²	Internal

8.2 Exposure controls

Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipment

i oroonar protootivo oquipino		
Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection		
Material	:	Chemical-resistant gloves
Remarks Skin and body protection	:	Consider double gloving. Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis- posable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection Filter type	:	If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 14387 Combined particulates and organic vapour type (A-P)
21 21		

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state	:	liquid, oily
Colour	:	No data available
Odour	:	No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Vers 5.2	sion	Revision Date: 04.12.2023		S Number: 827-00018	Date of last issue: 30.09.2023 Date of first issue: 16.06.2016
	Odour ⁻	Threshold	:	No data available	
	Melting	point/freezing point	:	No data available	3
	Initial be range	oiling point and boiling	:	No data available)
	Flamma	ability (solid, gas)	:	Not applicable	
	Flamma	ability (liquids)	:	No data available)
		explosion limit / Upper bility limit	:	No data available)
		explosion limit / Lower bility limit	:	No data available)
	Flash p	oint	:	No data available	
	Auto-ig	nition temperature	:	No data available)
	Decom	position temperature	:	No data available)
	рН		:	No data available)
	Viscosi Visc	ty osity, kinematic	:	No data available	9
	Solubili Wat	ty(ies) er solubility	:	No data available	9
	Partition octanol	n coefficient: n- /water	:	No data available	3
	Vapour	pressure	:	No data available)
	Density	,	:	No data available)
	Relative	e vapour density	:	No data available)
		characteristics icle size	:	No data available	
9.2	Other in	formation			
	Explosi	ves	:	Not explosive	
	Oxidizir	ng properties	:	The substance or	r mixture is not classified as oxidizing.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Versior 5.2	n Revision Date: 04.12.2023	SDS Number: 766827-00018	
E١	vaporation rate	: No data a	vailable
M	olecular weight	: No data a	vailable
SECT	ION 10: Stability and rea	ctivity	
	eactivity ot classified as a reactivity h	azard.	
	hemical stability able under normal condition	S.	
10.3 P	ossibility of hazardous rea	ctions	
Ha	azardous reactions	: Can react	with strong oxidizing agents.
10.4 C	onditions to avoid		
Co	onditions to avoid	: None kno	wn.
10.5 In	compatible materials		
	aterials to avoid	: Oxidizing	agents
No	azardous decomposition p o hazardous decomposition ION 11: Toxicological in	products are kr	nown.
	-		
	formation on hazard class formation on likely routes of		in Regulation (EC) No 1272/2008
	posure	Skin conta	ct
		Ingestion Eye conta	at
۵۵	cute toxicity	Lycoond	
	ot classified based on availa	ble information	
<u>Co</u>	omponents:		
Ce	efapirin:		
	cute oral toxicity	: LD50 (Mo	use): 26,000 mg/kg
	cute toxicity (other routes of Iministration)		use): > 7,600 mg/kg n Route: Intraperitoneal
): 7,800 mg/kg n Route: Intraperitoneal
pr	ednisolone:		
Ac	cute oral toxicity	: LD50 (Mo	use): 1,680 mg/kg



sion	Revision Date: 04.12.2023		0S Number: 6827-00018	Date of last issue: 30.09.2023 Date of first issue: 16.06.2016
			LD50 (Rat): > 3,8	57 mg/kg
Acute	inhalation toxicity	:	Remarks: No data	a available
Acute	dermal toxicity	:	Remarks: No data	a available
	toxicity (other routes of histration)	:	LD50 (Rat): 147 n Application Route	
			LD50 (Mouse): 76 Application Route	
-	corrosion/irritation assified based on availa	ble	information.	
Comp	oonents:			
predr Rema	nisolone: arks	:	No data available	
	us eye damage/eye irri assified based on availa			
Comp	oonents:			
pred n Rema	nisolone: arks	:	No data available	
Respi	iratory or skin sensitis	atio	n	
	sensitisation assified based on availa	ble	information.	
-	iratory sensitisation ause allergy or asthma	sym	ptoms or breathing	difficulties if inhaled.
<u>Comp</u>	oonents:			
Cefap				
Asses	ssment	:	Probability or evic humans	lence of high respiratory sensitisation rate
predr	nisolone:			
_	arks	:	No data available	
Rema				
Germ	assified based on availa	ble	information.	



ersion 2	Revision Date: 04.12.2023		9S Number: 6827-00018	Date of last issue: 30.09.2023 Date of first issue: 16.06.2016
Geno	toxicity in vitro	:	Test Type: Bacte Result: negative	rial reverse mutation assay (AMES)
predr	nisolone:			
-	toxicity in vitro	:	Test Type: Bacte Result: negative	rial reverse mutation assay (AMES)
			Test Type: Mouse Result: negative	e Lymphoma
			Test Type: sister Result: negative	chromatid exchange assay
Geno	toxicity in vivo	:	Test Type: Mamr cytogenetic assay Species: Rat Application Route Result: negative	
			Test Type: sister Species: Humans Result: negative	chromatid exchange assay
	nogenicity lassified based on avai	ilable	information.	
<u>Com</u>	ponents:			
predr	nisolone:			
Speci		:	Rat	
	cation Route sure time	:	Oral 18 Months	
Resu		:	negative	
•	oductive toxicity lassified based on avai	ilable	information.	
<u>Com</u>	<u>oonents:</u>			
Cefap	oirin:			
Effect	ts on fertility	:	Species: Rat Application Route	ty/early embryonic development e: Intraperitoneal injection > 500 mg/kg body weight s on fertility
Effect ment	ts on foetal develop-	:	Species: Rat Application Route	yo-foetal development e: Intraperitoneal injection oxicity: LOAEL: > 200 mg/kg body weight



Vers 5.2	sion	Revision Date: 04.12.2023		9S Number: 6827-00018	Date of last issue: 30.09.2023 Date of first issue: 16.06.2016
	•	solone: on fertility	:	Species: Rat Application Route	1 mg/kg body weight
	Effects ment	on foetal develop-	:	Species: Mouse Application Route Developmental To Result: Malformat	ro-foetal development : Oral oxicity: LOAEL: 0.5 mg/kg body weight ions were observed., Cleft palate ro-foetal development
				Species: Rat Application Route	: Oral oxicity: LOAEL: 30 mg/kg body weight
					: Subcutaneous oxicity: NOAEL: 25 mg/kg body weight on foetal development
	Reproc sessme	ductive toxicity - As- ent	:	Some evidence o animal experimen	f adverse effects on development, based on ts.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Components:

prednisolone:

Target Organs	:	Bone marrow, Adrenal gland, Liver
Assessment	:	Causes damage to organs through prolonged or repeated
		exposure.

Repeated dose toxicity

Components:

Cefapirin:

Species LOAEL Application Route Target Organs		Rat >= 200 mg/kg Intraperitoneal Blood
Remarks Species	:	anemia Dog

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

Version 5.2	Revision Date: 04.12.2023	SDS Number: 766827-00018	Date of last issue: 30.09.2023 Date of first issue: 16.06.2016	
Exp Tarç Spe LOA	lication Route osure time get Organs cies \EL	: 20 mg/kg : Oral : 4 Months : Gastrointestina : Dog : 100 mg/kg	al tract	
Exp Targ	lication Route osure time get Organs narks	: Intramuscular : 10 Months : Blood, Gastroi : anemia	ntestinal tract	
-	dnisolone:			
LÖA App Exp	cies NEL lication Route osure time get Organs	: Rat : 0.6 mg/kg : Oral : 63 Days : Bone marrow		
LÖA App Exp	cies \EL lication Route osure time get Organs	: Dog : 2.5 mg/kg : Oral : 6 Weeks : Adrenal gland		
LÖA App Exp	cies \EL lication Route osure time get Organs	: Rabbit : 1 mg/kg : Oral : 24 Weeks : Liver		
-	iration toxicity classified based on ava	ilable information.		
11.2 Info	rmation on other haz	ards		
_				

Endocrine disrupting properties

Product:

Assessment

: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:

Cefapirin:

Ingestion

: Symptoms: Nausea, Vomiting, Abdominal pain, Diarrhoea, vaginitis, colitis, anorexia, Rash, anaphylaxis

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

Version 5.2	Revision Date: 04.12.2023		DS Number: 6827-00018	Date of last issue: 30.09.2023 Date of first issue: 16.06.2016
predn Ingest	isolone: ion	:		um retention, Headache, Vertigo, fluid reten- us bleeding, striae, skin atrophy, menstrual
SECTION	12: Ecological infor	ma	ition	
12.1 Toxic	ity			
<u>Comp</u>	onents:			
predn	isolone:			
	y to daphnia and other c invertebrates	:	EC50 (Daphnia n Exposure time: 4	nagna (Water flea)): > 85 mg/l 8 h
Toxicit plants	y to algae/aquatic	:	NOEC (Pseudoki mg/l Exposure time: 7	rchneriella subcapitata (green algae)): 160 2 h
			EC50 (Pseudokir mg/l Exposure time: 7	chneriella subcapitata (green algae)): > 160 2 h
	y to daphnia and other c invertebrates (Chron- sity)	:	NOEC: 0.23 mg/l Exposure time: 7 Species: Cerioda	
	stence and degradabil a available	ity		
2.3 Bioac	cumulative potential			
<u>Comp</u>	onents:			
Partitic	isolone: on coefficient: n- I/water	:	log Pow: 1.46	
12.4 Mobil i No dat	i ty in soil a available			
12.5 Resul	ts of PBT and vPvB as	sse	ssment	
<u>Produ</u> Asses		:	to be either persi	nixture contains no components considered stent, bioaccumulative and toxic (PBT), or nd very bioaccumulative (vPvB) at levels of

Product:

Assessment

: The substance/mixture does not contain components consid-



Version 5.2	Revision Date: 04.12.2023	SDS Number: 766827-00018	Date of last issue: 30.09.2023 Date of first issue: 16.06.2016		
		REACH Art (EU) 2017/2	e endocrine disrupting properties according to icle 57(f) or Commission Delegated regulation 2100 or Commission Regulation (EU) 2018/605 at 1% or higher.		
	e r adverse effects ata available				
SECTIO	N 13: Disposal cons	siderations			
13.1 Was	te treatment methods	5			
Product Contaminated packaging		According t are not pro Waste code discussion Do not disp : Empty cont dling site fo	Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer. Empty containers should be taken to an approved waste han- dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.		
SECTIO	N 14: Transport info	ormation			
14.1 UN r	umber or ID number				
ADN		: Not regulat	ed as a dangerous good		
ADR		: Not regulat	ed as a dangerous good		
RID		: Not regulat	ed as a dangerous good		
IMDO	6	: Not regulat	ed as a dangerous good		
ΙΑΤΑ		: Not regulat	ed as a dangerous good		
14.2 UN p	proper shipping name	•			
ADN		: Not regulat	ed as a dangerous good		
ADR		: Not regulat	ed as a dangerous good		
RID		: Not regulat	ed as a dangerous good		
IMDO	3	: Not regulat	ed as a dangerous good		
ΙΑΤΑ		: Not regulat	ed as a dangerous good		
14.3 Tran	sport hazard class(es	s)			
ADN		: Not regulat	ed as a dangerous good		
ADR		: Not regulat	ed as a dangerous good		
RID		: Not regulat	ed as a dangerous good		
IMDO	3	: Not regulat	ed as a dangerous good		

:

Not regulated as a dangerous good

ΙΑΤΑ



Version 5.2	Revision Date: 04.12.2023	SDS Nur 766827-(Date of last issue: 30.09.2023 Date of first issue: 16.06.2016
14.4 Pack	ing group			
ADN		: Not r	egulated a	s a dangerous good
ADR		: Not r	egulated a	s a dangerous good
RID		: Not r	egulated a	s a dangerous good
IMDG	6	: Not r	egulated a	s a dangerous good
ΙΑΤΑ	(Cargo)	: Not r	egulated a	s a dangerous good
ΙΑΤΑ	(Passenger)	: Not r	egulated a	s a dangerous good
14.5 Envi	ronmental hazards			

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Maritime transport in bulk according to IMO instruments

Remarks

: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)	:	Conditions of restriction for the fol- lowing entries should be considered: Number on list 75, 3
		If you intend to use this product as tattoo ink, please contact your ven- dor.
		Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their

in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or not

		not.
REACH - Candidate List of Substances of Very High	:	Not applicable
Concern for Authorisation (Article 59).		
Regulation (EC) No 1005/2009 on substances that de-	:	Not applicable
plete the ozone layer		
Regulation (EU) 2019/1021 on persistent organic pollu-		Not applicable
tants (recast)	•	
		Net en Reele
Regulation (EC) No 649/2012 of the European Parlia-	:	Not applicable
ment and the Council concerning the export and import		
of dangerous chemicals		
REACH - List of substances subject to authorisation		Not applicable
(Annex XIV)	•	not applicable

Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	04.12.2023	766827-00018	Date of first issue: 16.06.2016

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances. Not applicable

Other regulations:

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventorie

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information	:	Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
Full text of H-Statements		
H302	:	Harmful if swallowed.
H334	:	May cause allergy or asthma symptoms or breathing difficul- ties if inhaled.
H361d	:	Suspected of damaging the unborn child.
H372	:	Causes damage to organs through prolonged or repeated exposure.
H411	:	Toxic to aquatic life with long lasting effects.
Full text of other abbreviatio	ons	
Acute Tox.	:	Acute toxicity
Aquatic Chronic	:	Long-term (chronic) aquatic hazard
Repr.	:	Reproductive toxicity
Resp. Sens.	:	Respiratory sensitisation
STOT RE	:	Specific target organ toxicity - repeated exposure
IE OEL	:	List of Chemical Agents and Carcinogens with Occupational Exposure Limit Values - Code of Practice, Schedule 1 and 2
IE OEL / OELV - 8 hrs (TWA)	:	Occupational exposure limit value (8-hour reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergen-



Version	Revision Date:	SDS Number:	Date of last issue: 30.09.2023
5.2	04.12.2023	766827-00018	Date of first issue: 16.06.2016

cy Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to :	Internal technical data, data from raw material SDSs, OECD
compile the Safety Data	eChem Portal search results and European Chemicals Agen-
Sheet	cy, http://echa.europa.eu/

H334

Classification of the mixture:

Resp. Sens. 1

Classification procedure:

Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN